HIV antiretroviral therapy: $36,000 a year versus $110

Modern antiretroviral therapy converts HIV into a manageable chronic condition. With sustained viral suppression, life expectancy approaches that of the general population, and a person with an undetectable viral load does not transmit the virus sexually.

That makes treatment both an individual and a public-health intervention — which is precisely why global access mechanisms were built for it earlier and more comprehensively than for almost any other disease.

Voluntary licensing, pooled procurement and generic competition reduced the annual cost of first-line therapy from thousands of dollars to a low double-digit figure in supplied countries. UNAIDS and the Global Fund document that trajectory.

Newly diagnosed, employed, insured with a high-deductible plan, and quoted a specialty-tier cost that made the first months of therapy unaffordable at the exact moment treatment should begin promptly.

Delay is the specific risk here. Early treatment initiation improves outcomes and reduces transmission, so a financial barrier at diagnosis has consequences beyond the individual.

His clinic connected him to programmes that exist precisely for this gap. He did not import anything.

1. 1Same-week treatment initiation using clinic-held starter supply.
2. 2Enrolment in a national HIV medication assistance programme.
3. 3Application to the manufacturer's patient assistance scheme as a parallel route.
4. 4Switch to a generic single-tablet regimen once available on his formulary.
5. 5Viral load monitoring at defined intervals to confirm suppression.
6. 6Adherence support, since single-tablet regimens depend on consistent daily dosing.

HIV therapy is unforgiving of irregular dosing. Inconsistent adherence allows viral replication in the presence of drug, which selects for resistance — and resistance narrows future options and pushes you toward more expensive second-line regimens.

So the cost strategy and the clinical strategy point the same way: whatever route makes daily uninterrupted dosing sustainable for years is the correct one, even if a marginally cheaper route exists.

He achieved an undetectable viral load within the expected timeframe and has maintained it. The assistance programme covered the initial period; the generic regimen made continuation sustainable.

The general lesson is that for HIV specifically, well-developed access infrastructure already exists in most countries. The first step is asking the clinic what is available, not searching for a cheaper supplier.

This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.

We publish these because abstract percentages do not communicate what a price gap means to a household. A number like '98% cheaper' is forgettable. A monthly bill that drops from an impossible figure to an affordable one is not.

Nothing here is a recommendation to change your own treatment. Every switch described was made with a prescriber's involvement, and yours should be too.

Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.